reports
- Ingird Gafanhão
- Ingird Gafanhão
TRAVERE initiation of coverage SELL – USD17 TRAVERE SELL – USD17 TP...
TRAVERE initiation of coverage SELL – USD17 TRAVERE SELL – USD17 TP | More questions than answers – A contrary view on sparsentan PDUFA Drug development in IgAN has intensified over the recent years, with several clinical trials ongoing, and early data showing encouraging proteinuria benefits. Travere has one of the more advanced clinical assets, after the company pivoted sparsentan into a phase 3 trial and filed for accelerated/conditional approval on the back of interim data. The PDUFA in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.